MULTIDRUG RESISTANT TUBERCULOSIS IN THE NORTHERN STATES OF MALAYSIA - A RETROSPECTIVE CASE SERIES FROM 2011 - 2016

Respirology ◽  
2017 ◽  
Vol 22 ◽  
pp. 216-216
Keyword(s):  
Case Series ◽  
Multidrug Resistant ◽  
Retrospective Case ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Retrospective Case Series

scholarly journals Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia

2018 ◽  
Vol 51 (3) ◽  
pp. 1702550 ◽  
Author(s):  
Lorenzo Guglielmetti ◽  
Linda Barkane ◽  
Damien Le Dû ◽  
Dhiba Marigot-Outtandy ◽  
Jérôme Robert ◽  
...  
Keyword(s):  
Case Series ◽  
Multidrug Resistant ◽  
Safety And Efficacy ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis

scholarly journals A Step towards Control of Multidrug Resistant Tuberculosis: Hospital Based Study from Nashik India

2016 ◽  
Vol 12 (2) ◽  
pp. 34-38
Author(s):  
SV Gosavi ◽  
M Patil ◽  
B Almale ◽  
S Dugad
Keyword(s):  
Case Series ◽  
Previous Treatment ◽  
Multidrug Resistant ◽  
Research Centre ◽  
Retrospective Case ◽  
College Hospital ◽  
Medical College ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis ◽  
Mdr Tb

Introduction: The Global TB report (2012), estimates 73,000 MDR TB patients living in India, among them only 1,660 cases were notified and 68.4% cases were put on treatment. Hence, this study was conducted with objective to assess the treatment outcome of multi drug resistant Tuberculosis patients enrolled in DOTS plus (Cat-VI) site.Methodology: It is a retrospective case series of MDR-TB cases conducted at Dr. Vasantrao Pawar Medical College, Hospital & Research Centre, Nashik (Maharashtra). Information was collected on age, gender, HIV status, previous treatment of TB, weight of patient, refused to take treatment for Cat IV. Outcome was recorded in terms of cure rate, rate of failure, defaulter, treatment completed, switch to Cat V and death.Results: Among the study subject, majority of study subjects were male (65%) and highest proportion (49%) of MDR-TB was in 25-44 years of age. Out of 353 patient 241 (68.4%) were still on Cat IV in which 35% patient’s on intensive phase and 65% put on continuation phase while 12.8%, 13.5%, 4%, 1.1%, 3.6% & 0.5% patient were found to be defaulted, died, refused to take treatment, treatment completed, transfer out & switch to Cat V, respectively.Conclusion: In the present study, the majority of study subjects (99.4%) were previously treated for TB, we identified number of operational challenges in the treatment of MDR-TB like rate of defaulter, refuse to take treatment & deaths among MDR-TB patient was high. There is need to study correlates of these factors in details also need of operational research to improve MDR-TB treatment in India is considered as priority.SAARC J TUBER LUNG DIS HIV/AIDS, 2015 XII (2), page: 34-38

scholarly journals Extraspinal osteoarticular multidrug-resistant tuberculosis in children: A case series

2017 ◽  
Vol 107 (11) ◽  
pp. 983 ◽  
Author(s):  
G B Firth ◽  
J Lescheid ◽  
M Camacho ◽  
M Esteves ◽  
N Beylis ◽  
...  
Keyword(s):  
Case Series ◽  
Multidrug Resistant ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Tuberculosis In Children

scholarly journals Treatment of wounds colonized by multidrug resistant organisms in immune-compromised patients: a retrospective case series

2013 ◽  
Vol 7 (1) ◽  
pp. 28 ◽  
Author(s):  
Marco Pignatti ◽  
Giorgio Gerunda ◽  
Gianluca Rompianesi ◽  
Nicola De Ruvo ◽  
Fabrizio Di Benedetto ◽  
...  
Keyword(s):  
Case Series ◽  
Multidrug Resistant ◽  
Retrospective Case ◽  
Retrospective Case Series ◽  
Multidrug Resistant Organisms ◽  
Treatment Of Wounds ◽  
Compromised Patients

scholarly journals Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States

2019 ◽  
Vol 71 (4) ◽  
pp. 1010-1016 ◽  
Author(s):  
Sundari Mase ◽  
Terence Chorba ◽  
Samuel Parks ◽  
Ann Belanger ◽  
Felicia Dworkin ◽  
...  
Keyword(s):  
Adverse Events ◽  
Private Insurance ◽  
Case Series ◽  
The United States ◽  
Multidrug Resistant ◽  
Qtc Prolongation ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Mdr Tb ◽  
Culture Conversion

Abstract Background In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series. Methods Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events. Results Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre–extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment TB. All patients were non–US-born and 5/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26–116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%). Conclusions Of 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB.

Sign in / Sign up

Export Citation Format

Share Document